Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a clinical diagnosis of Tourette Syndrome (TS)~2. Have participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies~3. If using maintenance medication(s) for TS and/or TS spectrum diagnoses (e.g. obsessive-compulsive disorder \[OCD\], Attention-Deficit Hyperactivity Disorder \[ADHD\]), be on stable doses~4. Be in good general health~5. Subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study~Exclusion Criteria:~1. Have an active, clinically significant unstable medical condition within 1 month before screening~2. Have a known history of long QT syndrome or cardiac arrhythmia~3. Have a known history of neuroleptic malignant syndrome~4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)~5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors~6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7 days, before the start of the study~7. Have a known history of substance dependence, substance (drug) or alcohol abuse within 3 months before the start of the study~8. Have a significant risk of suicidal or violent behavior~9. Have received an investigational drug within 30 days before the start of the study or plan to use an investigational drug (other than NBI-98854) during the study~10. Are currently participating in another NBI-98854 clinical study~11. Are pregnant (for females)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NBI-98854 (Type: EXPERIMENTAL): NBI-98854 administered once daily for up to 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).